NeurologyLive Friday 5 — July 3, 2020
Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 3, 2020.
Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
1: Stroke Care Evolves During These Uncertain Times
Andrew Russman, DO, medical director, Comprehensive Stroke Center, Cleveland Clinic, and guest editor for NeurologyLive, provides insight on how stroke care has changed during the COVID-19 pandemic.
2: Severe COVID-19 in Multiple Sclerosis Linked to Disability Status, Age, Obesity
Notably, the cohort assessment did not identify a link between exposure to disease-modifying therapies and COVID-19 severity, while EDSS was associated with the highest variability of COVID-19 severe outcome, followed by age and obesity.
3: Long-Term Data for Cannabidiol in Dravet Syndrome
Anup Patel, MD, section chief, Pediatric Neurology, Nationwide Children's Hospital, shared insight on the open-label extension trial that analyzed long-term safety and efficacy with cannabidiol in patients with Dravet syndrome.
4: Telemedicine in Dementia Care: Here to Stay?
In part 2 of this interview, Jessica Zwerling, MD, MS, associate director of the Center for the Aging Brain at Montefiore Medical Center, anticipates life with telemedicine after the pandemic and describes the at-home advantage it gives clinicians.
5: Ocrelizumab Compared to Glatiramer Acetate and Dimethyl Fumarate for MS
Mark Freedman, MD, outlines a retrospective trial presented at the Consortium of Multiple Sclerosis Centers (CMSC) 2020 Meeting reviewing first-line ocrelizumab compared to glatiramer acetate and dimethyl fumarate for treatment of relapsing-remitting multiple sclerosis.
